Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Biomedical Research Models, Inc.  Contract Discovery and Preclinical Research
What Makes Us Different• Scientific Reputation and Expertise  ◦    $20M+ in United States Public Health Service       Gran...
Biomedical Research Models, Inc.•   Established in 1996•   OLAW assured - 1999•   AAALAC accredited - 2006•   USDA Registe...
Areas of ExpertiseAutoimmune Diseases        Neuro-Degenerative Diseases  • Type 1 Diabetes          •   Multiple Sclerosi...
Proprietary Rat Models:          Diabetes• BioBreeding Diabetic Prone (BBDP/Wor) Rat  ◦ > 85% spontaneous incidence of Typ...
Proprietary Rat Models:        Autoimmune Diseases• BioBreeding Diabetic Resistant (BBDR/Wor) Rat   ◦ T1D controls (0% T1D...
Colony Management• Genetic rodent capabilities  ◦   Mating & breeding  ◦   PCR genotyping / RT PCR  ◦   Quarantine rederiv...
Discovery ResearchHigh Throughput-Customized Screening• Species: mouse, rat, guinea pig, rabbit, dog, marmoset• Small mole...
Discovery Toxicology• Non-GLP    ◦   Discovery and early development support    ◦   Dose-ranging finding    ◦   Dose escal...
Laboratory Services•   Tissue culture and cell line maintenance•   Serological and immunochemistry analyses•   Immunoassay...
CredentialsPublications•   Tikhonenko M. et al., 2013. N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inh...
Upcoming SlideShare
Loading in …5
×

BRM, Contract Discovery and Preclinical Research

1,512 views

Published on

Biomedical Research Models, Inc. (BRM) is a biomedical research company located in Worcester, MA that offers pre-clinical research services (CRO/Contract Research Organization) to the health industry. From early discovery to early toxicology New Drug Application (NDA), BRM is able to conduct in vivo phases of nonclinical programs including: pharmacokinetics; in vivo lead compound screening; proof of concept; efficacy assessment; pharmacology; mechanism of action; early lead optimization toxicology; as well as provide supportive colony maintenance and on-site client room use agreements.

  • Be the first to comment

  • Be the first to like this

BRM, Contract Discovery and Preclinical Research

  1. 1. Biomedical Research Models, Inc. Contract Discovery and Preclinical Research
  2. 2. What Makes Us Different• Scientific Reputation and Expertise ◦ $20M+ in United States Public Health Service Grants/Contracts ◦ Preclinical Testing Contract for Type 1 Diabetes• Model Development• IP- Proprietary Animal Models ◦ Metabolic and Autoimmune Diseases• Colony Management and Dedicated Use Agreements ◦ Favorable Discovery Model• Focused on Helping Nominate Drug Candidates for Development
  3. 3. Biomedical Research Models, Inc.• Established in 1996• OLAW assured - 1999• AAALAC accredited - 2006• USDA Registered - 2008• Worcester, MA location~45 FTEs
  4. 4. Areas of ExpertiseAutoimmune Diseases Neuro-Degenerative Diseases • Type 1 Diabetes • Multiple Sclerosis • Lupus • Diabetic Neuropathies • Rheumatoid Arthritis • Diabetic Encephalopathies • Multiple Sclerosis • Alzheimer Disease • Amyotrophic Lateral • Amyotrophic Lateral Sclerosis Sclerosis • Inflammatory Inflammation and Pain Bowel Disease • Delayed-type hypersensitivity • Rheumatoid ArthritisMetabolic Diseases • Inflammatory Bowel Disease • Type 2 Diabetes • Osteoarthritis • Metabolic Syndrome • Wound Healing • Obesity • Dyslipidemia Virology • Renal Models • Virus Infection Models • Vaccines/Antiviral
  5. 5. Proprietary Rat Models: Diabetes• BioBreeding Diabetic Prone (BBDP/Wor) Rat ◦ > 85% spontaneous incidence of Type 1 Diabetes (T1D) ◦ Diabetic complications including neuropathies, retinopathy and encephalopathys (cognition)• BioBreeding Zucker Diabetic Rat (BBZDR/Wor) ◦ Males develop obesity & Type 2 Diabetic (T2D) • Similar to ZDF, plus inbred and hypertensive • Develops diabetic complications including: retinopathy, neuropathy, atherosclerosis and end stage renal disease (ESRD) • Alzheimer’s disease ◦ Females develop obesity and Metabolic Syndrome
  6. 6. Proprietary Rat Models: Autoimmune Diseases• BioBreeding Diabetic Resistant (BBDR/Wor) Rat ◦ T1D controls (0% T1D incidence in VAF housing) ◦ Inducible Autoimmunity • Viral Induced Autoimmunity (VIA) • TLR modeling • Rheumatoid Arthritis (RA)• Multiple Autoimmune Disease (MAD) Rat ◦ 2010 Awarded NIH grant to characterize IBD, RA ◦ ~2-3% spontaneous incidence of T1D ◦ VIA by β herpes virus or parvovirus ◦ TLR modeling• WAG.rnu ◦ Aythmic nude rat ◦ Used for transplantation and adoptive transfer ◦ “Super nude” via proprietary treatment
  7. 7. Colony Management• Genetic rodent capabilities ◦ Mating & breeding ◦ PCR genotyping / RT PCR ◦ Quarantine rederivation ◦ Embryo transfer & cesarean rederivation ◦ Procedural manipulations ◦ Pharmacology & toxicology• Semi-rigid isolator animal housing• In vitro Laboratories
  8. 8. Discovery ResearchHigh Throughput-Customized Screening• Species: mouse, rat, guinea pig, rabbit, dog, marmoset• Small molecule, peptide, proteins and cell-based products• In vitro and ex vivo assays• Acute, repeat dosing and infusion• PK/PD parameters (non-compartmental and compartmental)• Fluid collections (blood, urine, CSF, etc…) including microdialysis• Dose linearity and tolerability• Abbreviated protocol• One-week turn around time
  9. 9. Discovery Toxicology• Non-GLP ◦ Discovery and early development support ◦ Dose-ranging finding ◦ Dose escalation and tolerability ◦ Drug exposure• Acute single dose, 7 or 14 days• Chronic dose, 7 – 14 days• Clinical pathology and chemistry• Gross necropsy with limited or extensive histopathology
  10. 10. Laboratory Services• Tissue culture and cell line maintenance• Serological and immunochemistry analyses• Immunoassays (ELISA, EIA)• Histology and immunohistochemistry• Flow cytometry/FACS Analysis• PCR/Real time PCR ◦ DNA/RNA extraction• Fluid analysis ◦ Blood ◦ Urine ◦ CSF ◦ Tissue homogenization ◦ Cell isolation
  11. 11. CredentialsPublications• Tikhonenko M. et al., 2013. N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. PLoS One. 8 (1):e55177. Epub 2013 Jan 29.• Christian W. Grant et al., 2012. Development of Standardized Insulin Treatment Protocols for Spontaneous Rodent Models of Type 1 Diabetes. Comparative Medicine. 62: 381-390.• Mordes JP, Bortell R, Guberski DL, Rossini AA, Greiner DL. Autoimmune diabetes mellitus in the BB rat. In: Sima AAF, Shafrir E, eds. Frontiers in animal diabetes research, Primer on animal models of diabetes. Reading, UK: Hardwood Academic Publishers; 1-41.• Yang K, Whalen BJ,, Tirabassi R, et al., A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. J Immunol. 2008 May 1;180(9):6159-67.Presentations• Christian W. Grant, Lisa M. Spain, Catherine Moran-Paul, Shane Duclos, Dennis L. Guberski, Guillermo Arreaza-Rubin. Results From The NIDDK Preclinical Testing Program For Prevention and Reversal of Type 1 Diabetes. Focis 2012• Christian W. Grant, Catherine Moran-Paul, Shane K. Duclos, Rebecca S. Tirabassi1, Lisa M. Spain, Guillermo Arreaza-Rubin, and Dennis L. Guberski. Increased severity of insulitis without decrease in beta cell mass in pre-diabetic non-obese diabetic (NOD) mice with impaired glucose tolerance. QUAD 2012• Barak Yahalom, Barbara Whalen, Maria L. Pedersen, James E. Staruk, Christian W. Grant, and Joan F. Flanagan. Validation of a Reproducible Animal Model for Crohn’s Disease. IRA 2012• Kari E. Harbert, Melissa M. Haskell, DVM, and Alain Stricker-Krongrad, Ph.D. Using the Conscious Guinea Pig to Evaluate human Ether-à-go-go Related Gene (hERG) Channel Blockers. QUAD 2012

×